Table 1.
Patient and graft characteristics
| Patient characteristic | Entire cohort (n = 125) | Neutrophil recovery at time of IMV (n = 72) | Neutrophil recovery after initiation of IMV (n = 26) | Never had neutrophil recovery (n = 27) | p value |
|---|---|---|---|---|---|
| Age at ICU admission (years) | 7.3 (0.2–20.9) | 8.1 (0.4–20.9) | 7.1 (0.2–20.8) | 7.3 (0.2–20.9) | 0.7053 |
| First HCT | 102 (81.6%) | 58 (80.6%) | 24 (92.3%) | 20 (74.1%) | 0.2169 |
| Transplant source | 0.0424 | ||||
| Bone marrow | 59 (47.2%) | 33 (45.8%) | 15 (57.7%) | 11 (40.7%) | |
| Cord | 49 (39.2%) | 24 (33.3%) | 10 (38.5%) | 15 (55.6%) | |
| Peripheral blood | 17 (13.6%) | 15 (20.8%) | 1 (3.8%) | 1 (3.7%) | |
| Related donor | 26 (20.8%) | 21 (29.2%) | 1 (3.8%) | 4 (14.8%) | 0.0167 |
| Malignant diagnosis | 68 (54.4%) | 44 (61.1%) | 15 (57.7%) | 9 (33.3%) | 0.0439 |
| Diagnosis leading to transplant | |||||
| Acute lymphoblastic leukemia | 31 (25%) | 19 (26%) | 8 (31%) | 4 (15%) | 0.3606 |
| Acute myeloid leukemia | 25 (20%) | 16 (22%) | 6 (23%) | 3 (11%) | 0.4253 |
| Primary immunodeficiency | 18 (14%) | 11 (15%) | 3 (12%) | 4 (15%) | 0.9413 |
| Hemophagocytic lymphohistiocytosis | 13 (10%) | 5 (7%) | 3 (12%) | 5 (19%) | 0.2156 |
| Bone marrow suppression | 12 (10%) | 6 (8%) | 1 (4%) | 5 (19%) | 0.2311 |
| Metabolic/genetic | 10 (8%) | 3 (4%) | 3 (12%) | 4 (15%) | 0.1452 |
| Myelodysplastic syndrome | 6 (5%) | 6 (8%) | 0 (0%) | 0 (0%) | 0.1330 |
| Lymphomas | 5 (4%) | 3 (4%) | 1 (4%) | 1 (4%) | 0.9999 |
| Hemoglobinopathies | 2 (2%) | 2 (3%) | 0 (0%) | 0 (0%) | 0.9999 |
| Other/not specified | 3 (2%) | 1 (1%) | 1 (4%) | 1 (4%) | 0.3860 |
| Days since HCT at IMV | 23 (0.0–69.0) | 36 (8–69) | 12 (5–47) | 12 (0–57) | <0.0001 |
| Present at PICU admission | |||||
| Respiratory distress | 108 (86.4%) | 59 (82.0%) | 25 (96.2%) | 24 (88.9%) | 0.1769 |
| Hemodynamic instability | 19 (15.2%) | 10 (13.9%) | 2 (7.7%) | 7 (26.0%) | 0.1618 |
| Altered mental status or seizures | 11 (8.8%) | 8 (11.1%) | 1 (3.8%) | 2 (7.4%) | 0.5119 |
| Respiratory pathogen identified | 43 (34.4%) | 25 (34.7%) | 11 (42.3%) | 7 (25.9%) | 0.4532 |
| Receiving supplemental O2 7 days prior to IMV | 46 (36.8%) | 32 (44.4%) | 8 (30.8%) | 6 (22.2%) | 0.0962 |
Results are presented in medians with (ranges) or in counts with (percentage)